核糖体蛋白 L23参与肿瘤进程的研究

Research of ribomomal protein L23 in tumor progression

核糖体蛋白 L23是肿瘤基因治疗的新靶点，其通过调控 p53激活、灭活鼠双微体2、间接影响 c-Myc 致癌活性、参与肿瘤多药耐药、影响肿瘤生物学行为等方式参与肿瘤进程，是影响肿瘤患者临床预后的潜在因素。

Ribosomal protein L23 is a new target for gene therapy of cancer.It participates in tumor progression by activating p53,inactivating murine double minute 2,regulating the carcinogenic activity of c-Myc,inducing the multi-drug resistance,and affecting the biologic behaviour of tumors.Generally,it′s con-sidered to be a potential prognostic factor in human cancers.